Sign In
Buy MCK
$763.91
+18.79 (+2.52%)
At Close: Jun 23, 2026
Merit Medical (MMSI) Launches New Soft Tissue Biopsy System
04:04pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Merit Medical's (MMSI) launch of the TEMNO Elite Soft Tissue Biopsy System will boost its portfolio of biopsy devices.
Zacks.com featured highlights include Hyatt Hotels, McKesson and Carlsberg
12:16pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Hyatt Hotels, McKesson and Carlsberg are part of Zacks Screen of the Week article.
PacBio's (PACB) New Method for TR Profiling Now Available
05:08pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.
3 Reasons to Hold Accuray (ARAY) Stock in Your Portfolio
03:48pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips
03:41pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.
Here's Why Investors Should Hold Exact Sciences (EXAS) Stock
03:37pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.
Stryker (SYK) Launches Q Guidance System for Spine Applications
03:12pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during guided spine surgery following its launch.
3 Reasons to Retain CONMED (CNMD) Stock in Your Portfolio
02:46pm, Wednesday, 28'th Sep 2022 Zacks Investment Research
Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.
3 Stocks With Upgraded Broker Ratings for Impressive Returns
11:54am, Wednesday, 28'th Sep 2022 Zacks Investment Research
As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select Hyatt Hotels (H), McKesson (MCK) and Carlsberg (CABGY) as these have seen rating upgrades
3 Stocks With Upgraded Broker Ratings for Impressive Returns
09:02am, Wednesday, 28'th Sep 2022
As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select Hyatt Hotels (H), McKesson (MCK) and Carlsberg (CABGY) as these have seen rating upgrades
3 Defensive Stocks To Watch Before October 2022
09:56pm, Tuesday, 27'th Sep 2022
Could now be the time to buy these defensive stocks as the stock market hits fresh new 52-week lows today.
PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows
03:44pm, Tuesday, 27'th Sep 2022 Zacks Investment Research
PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
03:42pm, Tuesday, 27'th Sep 2022 Zacks Investment Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
03:01pm, Tuesday, 27'th Sep 2022 Zacks Investment Research
Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
02:54pm, Tuesday, 27'th Sep 2022 Zacks Investment Research
Integer Holdings (ITGR) continues to gain momentum from robust medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.
